{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:15:09Z","timestamp":1794564909120,"version":"4.9.1"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:p>There is a growing population of pediatric and adult patients supported with the HeartMate 3 ventricular assist device (HM3 VAD) all of whom require anticoagulation. Apixaban is an anticoagulant requiring less testing than warfarin which has been shown to be effective in other indications. We report five pediatric and young adult patients managed on HM3 VAD with apixaban anticoagulation for 1589 days of VAD support between January 6, 2019 and January 7, 2022. The median age was 17 years and the weight was 69\u2009kg. Four patients had congenital heart disease (2 single-ventricle Fontan circulation, and 2 biventricular circulations) and one had dilated cardiomyopathy. Apixaban was initiated at a median of 7 days postoperatively and doses were titrated based on peak apixaban-specific anti-Xa chromogenic analysis levels (goal 150\u2013250\u2009ng\/ml). All patients received aspirin 81\u2009mg daily. There was one major hemocompatibility-related event observed (outflow graft thrombus in the setting of medication nonadherence and chronic VAD infection); there was no major bleeding, death, or stroke. Three patients underwent heart transplantation and two remain on VAD support. In this limited series, apixaban paired with a level-based dosing regimen and low-dose aspirin provided safe and effective antithrombosis with only one hemocompatibility-related event related to medication non-adherence.<\/jats:p>","DOI":"10.1097\/mat.0000000000001889","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T21:00:45Z","timestamp":1676062845000},"page":"e267-e269","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Apixaban Anticoagulation in Children and Young Adults Supported With the HeartMate 3 Ventricular Assist Device"],"prefix":"10.1097","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2754-6797","authenticated-orcid":false,"given":"Ryan L.","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Cardiology, Boston Children\u2019s Hospital Boston, MA"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Cetatoiu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Boston Children\u2019s Hospital Boston, MA"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Esteso","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Boston Children\u2019s Hospital Boston, MA"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Ventresco","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Boston Children\u2019s Hospital Boston, MA"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Boston Children\u2019s Hospital Boston, MA"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Daly","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Boston Children\u2019s Hospital Boston, MA"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Blume","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Boston Children\u2019s Hospital Boston, MA"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Fynn-Thompson","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA; \u00a7Department of Cardiology, Harvard School of Medicine, Boston Children\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7589-6409","authenticated-orcid":false,"given":"Christina","family":"VanderPluym","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Boston Children\u2019s Hospital Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"R1-20250530","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/MAT.0000000000001650","article-title":"Apixaban: Alternative anticoagulation for HeartMate 3 ventricular assist device.","volume":"68","author":"Whitehouse","year":"2022","journal-title":"ASAIO J"},{"key":"R2-20250530","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism.","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"R3-20250530","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism.","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"R4-20250530","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/STROKEAHA.117.018395","article-title":"Real-World use of apixaban for stroke prevention in atrial fibrillation: A systematic review and meta-analysis.","volume":"49","author":"Proietti","year":"2018","journal-title":"Stroke"},{"key":"R5-20250530","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/ajh.25604","article-title":"Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.","volume":"94","author":"Wysokinski","year":"2019","journal-title":"Am J Hematol"},{"key":"R6-20250530","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct oral anticoagulants: evidence and unresolved issues.","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"R7-20250530","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: A clinical pharmacokinetic and pharmacodynamic review.","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"R8-20250530","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.healun.2016.03.005","article-title":"Adverse events in children implanted with ventricular assist devices in the United States: Data from the Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS).","volume":"35","author":"Rosenthal","year":"2016","journal-title":"J Hear Lung Transplant"},{"key":"R9-20250530","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"R10-20250530","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/asheducation-2018.1.399","article-title":"Management of thrombosis in children and neonates: practical use of anticoagulants in children.","volume":"2018","author":"Monagle","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R11-20250530","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0022-5223(97)70283-6","article-title":"Coagulation factor abnormalities after the Fontan procedure and its modifications.","volume":"113","author":"Jahangiri","year":"1997","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["ASAIO Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MAT.0000000000001889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T13:08:37Z","timestamp":1748610517000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MAT.0000000000001889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mat.0000000000001889","relation":{},"ISSN":["1058-2916"],"issn-type":[{"value":"1058-2916","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,10]]}}}